ADVA
8.9.2020 09:02:18 CEST | Business Wire | Press release
ADVA (FSE: ADV) today announced that the Luxembourg Commercial Internet Exchange (LU-CIX) is increasing the security and availability of its services with the ADVA ALM fiber monitoring solution. The technology provides real-time network visibility, enabling LU-CIX to quickly locate and resolve all fiber issues. Deployed in the internet exchange company’s backbone infrastructure, the ADVA ALM delivers comprehensive in-service assurance. It’s now empowering LU-CIX to accurately pinpoint areas of degradation, instantly initiate countermeasures and redirect traffic away from degraded optical paths. The compact and low-power solution helps avoid outages and enables LU-CIX to track its SLAs. ADVA’s partner Telindus, a brand of Proximus Luxembourg, also played a key role in the deployment.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200908005221/en/
“We needed a solution that delivers precise, automated, up-to-the-minute root-cause analysis combined with permanent measurement. That’s why we chose the ADVA ALM. It enables our team to tackle issues more quickly and efficiently, while also addressing an area of security exposure,” said Michel Lanners, CIO, LU-CIX. “One of the key advantages of the ADVA ALM is that it offers significant improvement without a major addition to our existing network. It delivers total insight and full control without significant investment. What’s more, the technology enables us to improve the integrity of our network and detect eavesdropping attacks. With the ADVA ALM, we can remotely measure attenuation and stay one step ahead of attacks using a splitter or bending coupler.”
The ADVA ALM is now delivering precise, real-time insight into the integrity and performance of LU-CIX’s optical transport infrastructure. With its ease of use and intuitive GUI, the in-service monitoring equipment provides complete network assurance, enabling the root cause of link outages to be immediately pinpointed. Issues can now be identified in seconds and the right measures engaged, saving the company both time and money. The ADVA ALM also makes it straightforward to separate faults with active devices from problems in the fiber plant. Another key advantage is its transparent, service-agnostic monitoring, which is completely independent of transported data. That means the ADVA ALM delivers complete assurance with no application interference.
“Our ALM now ensures that LU-CIX has an intricate understanding of its fiber network. For maintenance teams, that means no more false alarms, no unnecessary site visits and no wasted hours finding faults. Now problems can be diagnosed and dealt with long before they affect services. Not only will this help to reduce operational expenses and maximize resource efficiency, but it’s also a key tool for maintaining valuable SLAs,” commented Hartmut Müller-Leitloff, SVP, sales, EMEA, ADVA. “LU-CIX is crucial to Luxembourg’s internet sector and one of Europe’s key internet hubs. By harnessing our unique plug-and-play device to further enhance the stability and efficiency of its infrastructure, it can continue to provide a secure and trusted environment in the heart of Europe.”
“This deployment is already bringing major benefits to LU-CIX and its customers. It’s enabling the internet exchange to avoid performance issues by rapidly responding to defects and degradation in its fiber network. Now LU-CIX can proactively reroute traffic and operating teams can take targeted action to fix faults,” said William Malingrey, pre-sales consultant, network solutions, Telindus. “We’re committed to providing the most innovative technologies available to support our customers’ business strategies and digital transformation. The ADVA ALM is a uniquely affordable and space-efficient solution that makes a real difference. It’s now giving LU-CIX total visibility and control of its fiber assets and supporting simpler, more cost-efficient and more sustainable practices.”
About ADVA
ADVA is a company founded on innovation and focused on helping our customers succeed. Our technology forms the building blocks of a shared digital future and empowers networks across the globe. We’re continually developing breakthrough hardware and software that leads the networking industry and creates new business opportunities. It’s these open connectivity solutions that enable our customers to deliver the cloud and mobile services that are vital to today’s society and for imagining new tomorrows. Together, we’re building a truly connected and sustainable future. For more information on how we can help you, please visit us at www.adva.com .
About LU-CIX
LU-CIX, the LUxembourg Commercial Internet eXchange was founded in 2009 based on a not-for-profit membership association with an open and neutral philosophy. Its aim is to develop the Internet and support the data center community in Luxembourg. As well as providing the technical infrastructure LU-CIX also makes a major contribution to the Luxembourg Internet community through its leading industry event, Luxembourg Internet Days, which takes place in November every year and attracts over a thousand industry experts and decision makers from around the globe. LU-CIX also runs the datacenters-in-europe.com website, which provides a shared communication platform for all the players in the Luxembourg data center and Internet arena and promotes Luxembourg as the best place for your European data center and ICT business in the heart of Europe. More information at www.lu-cix.lu .
Published by:
ADVA Optical Networking SE, Munich, Germany
View source version on businesswire.com: https://www.businesswire.com/news/home/20200908005221/en/
Social Media:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
